-- 史密斯医疗（Smith & Nephew，股票代码：SNN）周二表示，一项临床试验的最新数据显示，其CARTIHEAL AGILI-C软骨修复植入物具有“令人信服”的长期疗效。 该公司表示，研究发现，在长达五年的所有测量时间点上，该植入物均优于标准手术治疗。接受该植入物治疗的患者在五年期间疼痛缓解更明显，生活质量也得到改善。声明还指出，在治疗后的两年、四年和五年，他们在日常活动、运动和娱乐方面也表现出更大的进步。 该公司补充说，该研究还发现，无论患者是否患有骨关节炎，其疗效都相似。 该公司表示，该植入物最近获得了一级现行程序术语代码（CPT代码），将于2027年1月1日生效。 史密斯医疗股价当日下跌近3.4%。
Price: $33.04, Change: $-1.17, Percent Change: -3.42%
National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."
Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.
XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.